Which statement best describes common strategies for delivering therapeutic genes and their safety concerns?

Which statement best describes common strategies for delivering therapeutic genes and their safety concerns?

• A. Non-viral methods alone are sufficient for all clinical applications.
• B. Viral vectors such as AAV or lentivirus or non-viral methods; concerns include insertional mutagenesis, immune response, and long-term expression control.
• C. Only non-viral methods are safe and free of immunogenicity.
• D. There are no safety concerns exist once a vector is approved.

Answer: (C)

The idea being tested is how gene delivery uses both viral and non-viral approaches and the safety trade-offs involved. Viral vectors like AAV and lentivirus can deliver genes efficiently and achieve longer-lasting expression, which is why they’re common in gene therapy. But they come with safety concerns: the possibility of insertional mutagenesis with integrating vectors, immune responses to viral components that can reduce effectiveness or cause adverse effects, and the challenge of tightly controlling long-term expression. Non-viral methods can be safer in some respects, often showing lower immunogenicity and avoiding genome integration, but they typically have lower delivery efficiency, can yield transient expression, and may still raise immune or off-target safety issues. So the most accurate statement is that common strategies include both viral and non-viral delivery, along with well-recognized safety considerations like insertional mutagenesis, immune responses, and the complexity of achieving controlled, durable expression. The other options describe extremes or ignore safety concerns, which doesn’t align with how gene delivery is actually approached.

The idea being tested is how gene delivery uses both viral and non-viral approaches and the safety trade-offs involved. Viral vectors like AAV and lentivirus can deliver genes efficiently and achieve longer-lasting expression, which is why they’re common in gene therapy. But they come with safety concerns: the possibility of insertional mutagenesis with integrating vectors, immune responses to viral components that can reduce effectiveness or cause adverse effects, and the challenge of tightly controlling long-term expression. Non-viral methods can be safer in some respects, often showing lower immunogenicity and avoiding genome integration, but they typically have lower delivery efficiency, can yield transient expression, and may still raise immune or off-target safety issues. So the most accurate statement is that common strategies include both viral and non-viral delivery, along with well-recognized safety considerations like insertional mutagenesis, immune responses, and the complexity of achieving controlled, durable expression. The other options describe extremes or ignore safety concerns, which doesn’t align with how gene delivery is actually approached.